GASTRIC ADENOCARCINOMA

This early-phase study tests whether a new drug called NRM-823 is safe and tolerable for people with advanced solid tumors that have not responded to other treatments. About 150 participants with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 al…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for patients with resectable stomach, esophageal, or gastroesophageal junction cancer. The goal is to see if this approach is safe and effe…

This study is the first time the experimental drug KK2269 is being tested in people. It aims to check the safety of KK2269 given alone or with the chemotherapy drug docetaxel. The trial involves about 101 adults with advanced solid tumors (like stomach, lung, or esophageal cancer…

This study is for people with stomach cancer that has spread to the lining of the abdomen. It compares standard chemotherapy given through a vein to the same treatment plus an extra chemotherapy drug (paclitaxel) delivered directly into the belly through a small port. The goal is…

This study looks at people with esophageal or stomach cancer that has spread to only a few spots in the body. After 4 months of standard chemotherapy, some will get local treatment (surgery or radiation) right away, while others will have 4 more months of chemo first. The goal is…

This study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…

This study tests whether adding the drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or GEJ cancer from returning. About 70 adults who have had their tumor removed will receive the combination for up to 16 cycles. The main goal is to see h…

This study tests a new drug called denikitug, either alone or with other treatments, for people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has spread or come back. About 120 participants will be randomly assigned to different treatme…

This study tests whether adding radiation or surgery to standard chemotherapy helps people with esophageal or stomach cancer that has spread to 3 or fewer spots in the body. About 100 participants will be randomly assigned to receive either chemotherapy alone or chemotherapy plus…

This study tests whether adding two targeted drugs (pembrolizumab and trastuzumab) to standard chemotherapy can improve outcomes for people with HER2+ cancer of the esophagus or stomach before surgery. About 49 adults with resectable tumors will receive the combination, then surg…

This study tests a new drug called IMC002 for people with advanced stomach cancer that has not responded to at least two prior treatments. The goal is to see if IMC002 can slow tumor growth and help patients live longer compared to standard care. About 150 adults with a specific …

This study tests whether a new drug, OBP-301, injected directly into tumors, can make the immunotherapy drug pembrolizumab work better for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is PD-L1-negative or has stopped responding to immunothera…

This study tests a treatment plan for people with stomach cancer that has spread to the lining of the abdomen. It combines chemotherapy before surgery, a special heated chemotherapy given during a keyhole procedure, and then surgery to remove the cancer. The goal is to see if thi…

This study tests whether adding a second round of targeted treatment (called cytoreductive intervention) after standard chemotherapy can help people with advanced upper GI cancers live longer without the disease getting worse. It is for patients whose cancer has spread but whose …

This early-stage study tests a new drug called IDE892, alone or with other medicines, in people with advanced solid tumors that lack a gene called MTAP. The goal is to see if the drug is safe and can shrink tumors. About 260 adults with certain cancers (like lung, stomach, bladde…

This study looks at whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (SOX) can help prevent stomach cancer from coming back after surgery. It involves 460 adults with a specific type of advanced stomach cancer (stage N3, PD-L1 positive). Participants wil…

This early-stage study tests whether adding a drug called aldesleukin (IL-2) to standard immunotherapy and chemotherapy can better control stomach cancer that has spread to the abdomen lining. About 15 adults with this condition will receive the combination. The goal is to see if…

This study tests a new mix of chemotherapy drugs and immunotherapy for people with advanced esophageal or stomach cancer. The goal is to see if this combination works better and causes fewer side effects than current treatments. About 52 adults with these cancers will take part.

This early-stage study tests a new treatment called DISP-10, which combines a virus and specially engineered immune cells, for people with advanced stomach, esophageal, or colorectal cancers that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 66 …

This study tests whether adding tadalafil (a drug often used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. About 10 adults with resectable cancer will take tadalafil alone for two weeks, then combine…

This study tests a new drug called BL-M07D1 in people with advanced stomach or gastro-esophageal junction cancer that has a specific marker (HER2-positive) and has stopped responding to first-line anti-HER2 therapy. About 490 adults will be randomly assigned to receive either BL-…

This study tests whether giving the drug paclitaxel before and after stomach removal surgery can help people with gastric cancer that has spread to the lining of the abdomen. About 30 adults with this advanced cancer will receive the drug directly into the abdomen and through a v…

This study tests a combination of an immunotherapy drug (adebrelimab) with three chemotherapy drugs given before and after surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can completely eliminate the tumor …

This study is testing a drug called zolbetuximab combined with chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The goal is to see if this combination can help control the disease longer. About 70 participants will be enrolled, an…

This study is testing whether adding a drug called fruquintinib to standard chemotherapy and trastuzumab can help control advanced HER2-positive stomach or gastroesophageal junction cancer. It is for people who have not had prior treatment for their metastatic disease. The goal i…

This early-stage study tests a new drug called BL-M05D1 in about 160 adults with advanced or metastatic solid tumors, including stomach, pancreatic, esophageal, and bile duct cancers. The main goals are to find safe doses and understand side effects. Participants must have tried …

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether adding surgery and radiation to standard chemotherapy can improve outcomes for people with stomach cancer that has spread to specific lymph nodes in the back of the abdomen. About 54 participants will receive either standard treatment or a combination of …

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …

This early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…

This early-phase trial tests a new drug called AVA6103 in about 144 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors to kill cancer cells while limiting…

This study tests a new way to treat stomach cancer that has spread to the lining of the abdomen. Doctors will use a robot to remove visible cancer and then deliver heated chemotherapy directly into the belly during surgery. The goal is to help patients recover faster and have few…

This study compares a new stool test that looks for high-risk gene changes in H. pylori bacteria with a standard risk questionnaire to see which method finds stomach cancer earlier. Researchers will enroll 15,000 adults aged 40 and older. Participants will provide a stool sample …

This study tests whether removing drainage tubes after laparoscopic stomach cancer surgery helps patients recover faster without increasing complications. About 454 adults with early to advanced stomach cancer will be randomly assigned to receive or skip the tubes. The goal is to…

This study is building a registry of 3,200 people with early stomach changes that can lead to cancer, such as gastric atrophy or intestinal metaplasia. Researchers will also include healthy people and those with stomach cancer for comparison. The goal is to learn which risk facto…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday medical practice in Germany. It will include about 1,900 adults who are starting their first palliative therapy. The g…